1. Home
  2. SSII vs NEO Comparison

SSII vs NEO Comparison

Compare SSII & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSII

SS Innovations International Inc.

HOLD

Current Price

$4.88

Market Cap

988.6M

Sector

N/A

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$7.55

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSII
NEO
Founded
N/A
2001
Country
India
United States
Employees
483
N/A
Industry
Precision Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
988.6M
1.2B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
SSII
NEO
Price
$4.88
$7.55
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$11.14
AVG Volume (30 Days)
58.5K
1.4M
Earning Date
03-10-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.63
Revenue Next Year
N/A
$9.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$4.72
52 Week High
$14.29
$13.74

Technical Indicators

Market Signals
Indicator
SSII
NEO
Relative Strength Index (RSI) 52.74 25.11
Support Level $4.31 $7.46
Resistance Level $5.18 $7.87
Average True Range (ATR) 0.30 0.36
MACD 0.01 0.04
Stochastic Oscillator 62.22 2.11

Price Performance

Historical Comparison
SSII
NEO

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: